

TRASYLOL FDA BIBLIOGRAPHY

1. Mangano, D et al. The Risk Associated with Aprotinin in Cardiac Surgery. *New England Journal of Medicine*. 354(4):353-65; January, 2006.
2. Karkouti, K et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. *Transfusion*. 46(3): 3:327-38; March, 2006.
3. i3 Preliminary Drug Safety Study Report. Mortality and Cardiovascular and Renal Outcomes in Recipients of Aprotinin, Aminocaproic Acid and Tranexamic Acid during CABG Surgery: Report on Computerized Inpatient Data from the Premier Prospective Comparative Database". On file with NDA 20304 as part of Bayer's submission dated September 27, 2006.
4. Mangano, D et al. Mortality Associated with Aprotinin during 5 Years following Coronary Artery Bypass Graft Surgery. *JAMA*. 297(5):471-479, 2007.
5. Coleman CI et al. Evaluating the safety implications of aprotinin use: The Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS). *The Journal of Thoracic and Cardiovascular Surgery*. 133:1547-1552, 2007.
6. Mazer D et al. Incidence of Massive Bleeding in a Blinded Randomized Controlled Trial of Antifibrinolytic Drugs in High Risk Cardiac Surgery. *Anest Analg*. 102:SCA 1-97, 2006.
7. Brown JR et al. Meta-Analysis comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery. *Circulation* 115:2801-2813, 2007
8. Shaw A et al. Long Term Survival Following Aprotinin Therapy in Cardiac Surgery. Annual Meeting of the American Society of Anesthesiologists, October 13, 2007. Abstract A242. San Francisco, CA